Clinical Trial

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Study acronym: MOMENTUM
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-09-03; most recent amendment 2026-07-17.
Status change: Not Yet Recruiting → Recruiting 2026-01-27
Trial Details
NCT Number NCT07155226
Lead Sponsor AstraZeneca
Conditions Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes
Enrollment 84 participants
Start Date 2026-01-09
Primary Completion 2029-02-15 (estimated)
Study Completion 2029-02-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-20